ReViral raises $21M in series A

ReViral Ltd. (Cardiff, U.K.) raised $21 million in a series A financing co-led by Edmond de Rothschild Investment Partners and OrbiMed. New investor Brace Pharma Capital also participated.

ReViral's lead candidate is RV521 to treat respiratory syncytial virus (RSV). The company plans to start IND-enabling studies next quarter of the RSV fusion inhibitor and hopes to begin clinical studies next year. ...